|
Revotar Biopharmaceuticals |
|
|
Neuendorfstrasse 24a
Hennigsdorf, 16761 Germany
phone:(49) (0) 3302 202 5010
fax:(49) (0) 3302 202 5011
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.revotar-ag.de
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drugs for asthma, psoriasis, sepsis, COPD and other inflammatory indications. |
|
| Management |
| Stephan Tarlach, M.Sc., MBA, CEO; Gerhard Wolff, MD, ExVP; Horst Witzel, Ph.D., Chairman, Chairman of the Board of Executive Directors; Oliver Borrmann, Chief Executive Officer, CEO; David Millhouse, Chief Executive Officer, CEO |
| |
|
|
| |
|
| Keywords |
| biopharmaceuticals, small molecule, molecule, anti-inflammatory, inflammatory, asthma, psoriasis, sepsis, copd, drugs |
|
|
|
| Description |
|
Revotar Biopharmaceuticals is a privately owned, independent German biopharmaceutical company which develops innovative small molecule anti-inflammatory drugs for indications such as asthma, psoriasis, sepsis, COPD and other inflammatory indications. |
|
| Products / Services |
Bimosiamose
|
|
| Technology / Differentiation |
| Revotar?s focus is on the discovery (rational drug design) and development of small molecule anti-inflammatory drug candidates for indications such as chronic obstructive pulmonary disease (COPD), asthma and acute lung injury (ALI). |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members